EPRX — Eupraxia Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- CA$562.52m
- CA$489.70m
Annual cashflow statement for Eupraxia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | C2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.6 | -19 | -29 | -25.7 | -38.6 |
| Depreciation | |||||
| Non-Cash Items | 7.04 | 2.97 | 2.75 | 2.4 | 10.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.169 | 1.51 | 5.35 | -6.76 | -0.714 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -11.7 | -14.4 | -20.7 | -30 | -28.6 |
| Capital Expenditures | -0.344 | -0.236 | -0.073 | -0.104 | -0.589 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -11.2 | 10.1 | 0 | 0.029 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -11.5 | 9.83 | -0.073 | -0.075 | -0.589 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 39.8 | 10.8 | 21.1 | 45.8 | 76.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 16.5 | 5.73 | 1.08 | 13.8 | 47.5 |